OR10A6: A Potential Drug Target and Biomarker (G390093)
OR10A6: A Potential Drug Target and Biomarker
OR10A6 is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and kidneys. Its full name is O10A6 gene 6, and it is a member of the superfamily of tight junction proteins (TJP). OR10A6 plays a critical role in the development and maintenance of tight junctions, which are specialized barriers that separate cells from their surrounding environment.
Tight junctions are essential for many physiological processes in the body, including the regulation of ion and solute transport, as well as the maintenance of tissue structure and the prevention of leakage. They are also involved in the regulation of cell-cell and cell-extracellular matrix interactions, as well as in the development and maintenance of various tissues and organs.
OR10A6 is a 21-kDa protein that consists of 151 amino acid residues. It has a characteristic hydrophobic domain that is involved in its stability and functions as a receptor for various signaling molecules, including cadherins, integrins, and selectins. OR10A6 is also known for its role in cell-cell adhesion, as it is a negative regulator of the cadherin/cathelin system, which is involved in the development and maintenance of tight junctions.
OR10A6 has been shown to be involved in many different physiological processes in the body, including the regulation of ion and solute transport, as well as the maintenance of tissue structure and the prevention of leakage. For example, studies have shown that OR10A6 is involved in the regulation of the transport of various ions and solutes, including potassium ions (K+), calcium ions (Ca2+), and protons (H+).
In addition, OR10A6 is also involved in the regulation of the formation and maintenance of tight junctions, as well as the regulation of cell-cell adhesion. Studies have shown that OR10A6 is a negative regulator of the cadherin/cathelin system, which is involved in the development and maintenance of tight junctions. This means that when OR10A6 is expressed in a cell, it can inhibit the activity of the cadherins and catheins, which are involved in the formation of tight junctions.
OR10A6 has also been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway and the Wnt pathway. This means that OR10A6 can interact with and regulate the activity of various proteins that are involved in these signaling pathways.
OR10A6 is also a potential drug target, as its regulation of tight junction formation and cell-cell adhesion makes it an attractive target for the development of new pharmaceuticals. Studies have shown that the expression of OR10A6 is significantly increased in various diseases, including cancer, and that its levels are also elevated in various types of cancer. This suggests that targeting OR10A6 with small molecules or other therapeutic agents may be an effective way to treat certain types of cancer.
In addition, OR10A6 has also been shown to be a potential biomarker for various diseases. Its regulation of tight junction formation and cell-cell adhesion makes it an attractive target for the development of new diagnostic tests for various types of cancer. Studies have shown that the expression of OR10A6 is significantly altered in various types of cancer, and that its levels are often elevated in these diseases. This suggests that using OR10A6 as a biomarker for cancer diagnosis and monitoring could be an effective way to improve the accuracy and effectiveness of cancer treatments.
Overall, OR10A6 is a protein that is involved in
Protein Name: Olfactory Receptor Family 10 Subfamily A Member 6 (gene/pseudogene)
Functions: Odorant receptor
The "OR10A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR10A6 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1
